Even as the global slowdown has severely impacted the biotech sector, one of india's largest pharma companies, Biocon, remains optimistic about the future growth. The company's promoter, Kiran Mazumdar Shaw is an exclusive interview to NDTV profit, said that opportunities are around the corner.

“We expect further tie ups between global pharma majors and Indian generic companies. There will be strong demand push from the US markets for generic products," said Kiran Mazumdar-Shaw, CEO & MD, Biocon.

Back home, Biocon is anxiously waiting to wrap up trials and get approval for its much-awaited oral insulin in India. The company expects to get Rs 500 crore of revenue if launched in the next fiscal. The company also expects to launch insulin based products in Europe by end 2011.

But it is not all just about the future. At the moment Biocon is all poised to service the increasing diabetic population in what is often referred to as the diabetes capital of the world – India. And with about 25 per cent of its sales coming from its glargine insulin clearly.it is a sweet success.